New Concepts in the Management of Medullary Thyroid Cancer - Management of Medullary Thyroid Cancer

This live webinar series is an educational program that addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with medullary thyroid cancer (MTC).

NCCN Tumor Boards: New and Emerging Systemic Therapy Options in Bladder Cancer
Systemic therapies are critical to the treatment of muscle-invasive bladder cancer (MIBC) and locally advanced/metastatic bladder cancer. Recent approvals and clinical trial results continue to enhance the treatment landscape in this space.
Optimizing Patient Outcomes - Transitioning CAR T-Cell and Bispecific Therapies to the Outpatient Setting
Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.
NCCN Tumor Boards: Exploring De-escalation of Radiation Therapy in the Management of Rectal Cancer
Education on de-escalation of radiation therapy for rectal cancer will highlight the most current clinical trial data and help clinicians identify which patients would be the best candidates for this new approach.
NCCN Tumor Boards: Skin Cancers Except Melanoma - Radiation Therapy Treatment Options

Isotope-based brachytherapy can be an effective treatment for certain sites of disease, particularly on the head and neck.

Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma

With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, un

Optimizing Patient Outcomes - Understanding the Mismatch Repair Deficient (dMMR)/Microsatellite-High (MSI-H) Treatment Options in Upper Gastrointestinal Cancers

The standards of care for the treatment of MSI-H/dMMR esophageal, esophagogastric junction, and gastric cancers are constantly evolving.

NCCN 2025 Nursing Program: Advancing Oncology Nursing™

This program will cover essential updates in clinical oncology practice, including emerging treatment modalities and patient management strategies.

NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.

Pages

Subscribe to RSS - Live Webinar